Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Diffuse midline gliomas (including diffuse intrinsic pontine glioma, DIPG) are highly morbid glial neoplasms of the thalamus or brainstem that typically arise in young children and are not surgically resectable. These tumors are characterized by a high rate of histone H3 mutation, resulting in replacement of lysine 27 with methionine (K27M) in genes encoding H3 variants H3.3 (H3F3A) and H3.1 (HIST1H3B). Detection of these gain-of-function mutations has clinical utility, as they are associated with distinct tumor biology and clinical outcomes. Given the paucity of tumor tissue available for molecular analysis and relative morbidity of midline tumor biopsy, CSF-derived tumor DNA from patients with diffuse midline glioma may serve as a viable alternative for clinical detection of histone H3 mutation. We demonstrate the feasibility of two strategies to detect H3 mutations in CSF-derived tumor DNA from children with brain tumors (n = 11) via either targeted Sanger sequencing of H3F3A and HIST1H3B, or H3F3A c.83 A > T detection via nested PCR with mutation-specific primers. Of the six CSF specimens from children with diffuse midline glioma in our cohort, tumor DNA sufficient in quantity and quality for analysis was isolated from five (83%), with H3.3K27M detected in four (66.7%). In addition, H3.3G34V was identified in tumor DNA from a patient with supratentorial glioblastoma. Test sensitivity (87.5%) and specificity (100%) was validated via immunohistochemical staining and Sanger sequencing in available matched tumor tissue specimens (n = 8). Our results indicate that histone H3 gene mutation is detectable in CSF-derived tumor DNA from children with brain tumors, including diffuse midline glioma, and suggest the feasibility of "liquid biopsy" in lieu of, or to complement, tissue diagnosis, which may prove valuable for stratification to targeted therapies and monitoring treatment response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., et al. (2012) · Nature · doi:10.1038/nature10833 · Cited by 2,631 · cited 2×
“3 G34V/R) The K27M mutation is observed in up to 80% of diffuse midline gliomas, and G34V/R mutations occurs in up to 30% of hemispheric pediatric gliomas [10, 20, 33, 38].”
BackgroundSt. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2012) · Nature Genetics · doi:10.1038/ng.1102 · Cited by 1,724
Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma
Lewis, P. W., Müller, M. M., Koletsky, M. S., Cordero, F., Lin, S., Banaszynski, L. A., Garcia, B. A., Muir, T. W., Becher, O. J., & Allis, C. D. (2013) · Science · doi:10.1126/science.1232245 · Cited by 1,345 · cited 2×
“In order to eliminate genomic DNA (gDNA) derived from white blood cells, which can potentially interfere or mask the signal of tumor-derived DNA [26], CSF specimens were centrifuged at 500 × g for five minutes at 4 °C within two hours of collection to isolate the cell-free supernatant, which has been shown to yield DN…”
MethodResultSubstantial biases in ultra-short read data sets from high-throughput DNA sequencing
Dohm, J. C., Lottaz, C., Borodina, T., & Himmelbauer, H. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn425 · Cited by 1,088 · cited 1×
“3K27M mutant H3F3A alleles from a total pool of H3F3A in order to prevent amplification bias of smaller-sized DNA fragments [6].”
BackgroundKhuong-Quang, D.-A., Buczkowicz, P., Rakopoulos, P., Liu, X.-Y., Fontebasso, A. M., Bouffet, E., Bartels, U., Albrecht, S., Schwartzentruber, J., Letourneau, L., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0998-0 · Cited by 1,028 · cited 1×
“Because patients with H3 mutations demonstrate a more aggressive clinical course and poorer overall response to therapy [3, 16, 20], the biological effects H3 mutations are thought to contribute to the lack of clinical response to treatments that are more effective in H3 wild type gliomas [16].”
BackgroundFunctionally defined therapeutic targets in diffuse intrinsic pontine glioma
Grasso, C. S., Tang, Y., Truffaux, N., Berlow, N. E., Liu, L., Debily, M.-A., Quist, M. J., Davis, L. E., Huang, E. C., Woo, P. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3855 · Cited by 687 · cited 1×
“Indeed, pre-clinical evaluation of agents aimed at the downstream effects of H3K27M in diffuse midline glioma demonstrate efficacy [11, 12, 27], and biopsy-based clinical trials for patient stratification to molecularly targeted treatments based on H3 mutation status are now underway [15, 17, 36].”
BackgroundEpigenetic balance of gene expression by Polycomb and COMPASS families
Piunti, A., & Shilatifard, A. (2016) · Science · doi:10.1126/science.aad9780 · Cited by 524
Self-citationPharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma
Hashizume, R., Andor, N., Ihara, Y., Lerner, R., Gan, H., Chen, X., Fang, D., Huang, X., Tom, M. W., Ngo, V., et al. (2014) · Nature Medicine · doi:10.1038/nm.3716 · Cited by 476
Self-citationTherapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas
Piunti, A., Hashizume, R., Morgan, M. A., Bartom, E. T., Horbinski, C. M., Marshall, S. A., Rendleman, E. J., Ma, Q., Takahashi, Y.-H., Woodfin, A. R., et al. (2017) · Nature Medicine · doi:10.1038/nm.4296 · Cited by 445 · cited 2×
“Indeed, pre-clinical evaluation of agents aimed at the downstream effects of H3K27M in diffuse midline glioma demonstrate efficacy [11, 12, 27], and biopsy-based clinical trials for patient stratification to molecularly targeted treatments based on H3 mutation status are now underway [15, 17, 36].”
BackgroundSelf-citationSpatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma
Nikbakht, H., Panditharatna, E., Mikael, L. G., Li, R., Gayden, T., Osmond, M., Ho, C.-Y., Kambhampati, M., Hwang, E. I., Faury, D., et al. (2016) · Nature Communications · doi:10.1038/ncomms11185 · Cited by 252
Cited by
Current state of immunotherapy for glioblastoma
Lim, M., Xia, Y., Bettegowda, C., & Weller, M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0003-5 · Cited by 1,365
Mangum, R., Reuther, J., Sen Baksi, K., Gandhi, I., Zabriskie, R. C., Recinos, A., Raesz-Martinez, R., Lin, F. Y., Potter, S. L., Sher, A. C., et al. (2023) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2023.2228837 · Cited by 8
Metadata
- Authors
- Huang, T. Y., Piunti, A., Lulla, R. R., Qi, J., Horbinski, C. M., Tomita, T., James, C. D., Shilatifard, A., & Saratsis, A. M.
- Venue
- Acta Neuropathologica Communications
- Published
- 2017-04-17
- Volume
- 5
- Issue
- 1
- Pages
- 28-28
- ISSN
- 2051-5960 (ISSN-L)
- OpenAlex
- W2606680370
- Cited by
- 176
- References
- 10
- FWCI
- 9.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma. https://app.cochat.ai/papers/10.1186/s40478-017-0436-6
- The paper
- Huang, T. Y., Piunti, A., Lulla, R. R., Qi, J., Horbinski, C. M., Tomita, T., James, C. D., Shilatifard, A., & Saratsis, A. M. (2017). Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma. Acta Neuropathologica Communications. https://doi.org/10.1186/s40478-017-0436-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.